Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)

Vertex Pharmaceuticals has reported Research & Development for 18 years, with the latest figure at $961.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 1.85% year-over-year to $961.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 billion (up 1.85% YoY), and the FY2025 full-year result was $3.9 billion, up 7.69% from the prior year.
• Research & Development for Q1 2026 stood at $961.6 million, down from $973.7 million in the prior quarter.
• The five-year high for Research & Development was $998.7 million in Q4 2024, with the low at $600.1 million in Q2 2022.
• Average Research & Development over 5 years is $835.6 million, with a median of $824.6 million recorded in 2023.
• Year-over-year, Research & Development surged 38.12% in 2022 and dropped 2.5% in 2025.
• Tracing VRTX's Research & Development over 5 years: stood at $694.1 million in 2022, then grew by 18.8% to $824.6 million in 2023, then advanced by 21.11% to $998.7 million in 2024, then declined by 2.5% to $973.7 million in 2025, then fell by 1.24% to $961.6 million in 2026.
• The last three Research & Development figures came in at $961.6 million (Q1 2026), $973.7 million (Q4 2025), and $977.7 million (Q3 2025), per Business Quant data.

Peer Comparison